Molecular Profile of Canine Hemangiosarcoma and Potential Novel Therapeutic Targets

• Published in: Veterinary sciences Vol. 10; no. 6; p. 387
• Main Authors: Pimentel, Pedro Antônio Bronhara, Giuliano, Antonio, Bęczkowski, Paweł Marek, Horta, Rodrigo Dos Santos
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.06.2023; MDPI
• Subjects: Abdomen; Angiosarcoma; Biopsy; CDKN2A; Chemotherapy; dog; Dogs; Genes; Hemorrhage; Histopathology; Kinases; Liver; Medical prognosis; Metastasis; Mutation; Neuroblastoma; NRAS; p53 Protein; Phosphatidylinositol 4,5-diphosphate; PIK3CA; PTEN protein; Review; Spleen; Surgery; Survival; Therapeutic applications; Therapeutic targets; Tumor proteins; Tumors; Vascular endothelial growth factor; Vascular endothelial growth factor receptors; VEGF; NRAS; PIK3CA; CDKN2A; VEGF; PTEN; angiosarcoma; TP53; dog
• ISSN: 2306-7381; 2306-7381
• DOI: 10.3390/vetsci10060387

Canine hemangiosarcoma (HSA) is a relatively common neoplasia, occurring mainly in the skin, spleen, liver and right atrium. Despite the numerous studies investigating the treatment of canine HSA, no significant improvement in survival has been achieved in the last 20 years. Advancements in genetic and molecular profiling presented molecular similarities between canine HSA and human angiosarcoma. It could therefore serve as a valuable model for investigating new and more effective treatments in people and dogs. The most common genetic abnormalities in canine HSA have been found in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) and neuroblastoma RAS viral oncogene homolog (NRAS) pathways. Mutations are also found in tumor protein p53 (TP53), phosphatase and tensin homolog (PTEN) and cyclin dependent kinase inhibitor 2A (CDKN2A). Known abnormal protein expression could be exploited to trial new target treatments that could be beneficial for both canine and human patients. Despite the high expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR), no correlation with overall survival time has ever been found. In this review, we explore the most recent developments in molecular profiling in canine HSA and discuss their possible applications in the prognosis and treatment of this fatal disease.